Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501407 | 0.86 | NPC1 (0.48) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL12501493 | 0.84 | CDK1 (0.49) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL12501291 | 0.83 | ALDH1A1 (0.56) | MAPTALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL26660694 | 0.81 | KDM4E (0.51) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL3493986 | 0.80 | KDM4E (0.50) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL3276252 | 0.78 | KDM4E (0.57) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL2661272 | 0.78 | XDH (0.58) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL1277858 | 0.76 | RAB9A (0.52) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL656156 | 0.76 | KDM4E (0.67) | MAPTALDH1A1HPGDNPC1KDM4E | |
| SCHEMBL2660383 | 0.75 | XDH (0.50) | MAPTALDH1A1HPGDNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838895-B1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9096579-B2 | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2838895-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156608-A1 | AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281430-A1 | Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments | INMT, IDO1, CHRM1 | MAPT 1321/4885ALDH1A1 893/4885HPGD 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.